Taltz (also known by its generic name ixekizumab) was approved for the treatment of moderate-to-severe plaque psoriasis in patients older than 6 years and older in 2016 and for adults with active psoriatic arthritis in 2017.
Taltz is given by injection under the skin. For adults with plaque psoriasis, the initial dose is given at week 0 (the first week of treatment) and at weeks 2, 4, 6, 8, 10, and 12, and then every 4 weeks afterward. For pediatric patients with plaque psoriasis, the initial dose is given at week 0 (the first week of treatment) and then every 4 weeks afterward. For adults with psoriatic arthritis, the initial dose is given at week 0 (the first week of treatment) and then every 4 weeks afterward.
To learn more, please visit the Taltz website.
